09:52 AM EST - Tribute Pharmaceuticals Canada Inc. : announced that it has received a patent approval from the European Patent Office for intellectual property central to one of the Company's lead products, Uracyst®/Uropol® (a sterile sodium chondroitin sulfate solution, 2%), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Tribute Pharmaceuticals Canada Inc.
shares V.TRX are trading unchanged at $0.50.
